iBio says single-dose IBIO-610 cuts active Activin E 98% through eight weeks in obese primate study

iBio, Inc.

iBio, Inc.

IBIO

0.00
  • iBio disclosed new preclinical results for IBIO-610, a long-acting antibody candidate targeting Activin E for obesity.
  • Findings were not yet presented; the full dataset is scheduled for release at the EASD Annual Meeting on Oct. 1.
  • A single dose produced sustained target suppression for weeks, supporting a low-frequency dosing profile.
  • In combination with semaglutide, IBIO-610 improved fat loss while limiting lean mass loss versus semaglutide alone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010700PRIMZONEFULLFEED9755082) on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.